Derek J. Eberwein

Chemistry · Physical Sciences

7h-index834citations21works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Synthesis and biological activity(8), Synthesis of Tetrazole Derivatives(8), PI3K/AKT/mTOR signaling in cancer(5), Melanoma and MAPK Pathways(4), Synthesis and Reactions of Organic Compounds(4)

Publications21 total

Supplementary Figure 2 from Characterization of an Akt Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity
2023Open Access
Supplementary Figure 2 from Characterization of an Akt Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity
2023Open Access
Supplementary Methods and Figure Legends 1-2 from Characterization of an Akt Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity
2023Open Access
Data from Characterization of an Akt Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity
2023Open Access
Supplementary Methods and Figure Legends 1-2 from Characterization of an Akt Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity
2023Open Access
Data from Characterization of an Akt Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity
2023Open Access
Supplementary Figure 1 from Characterization of an Akt Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity
2023Open Access
Supplementary Figure 1 from Characterization of an Akt Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity
2023Open Access
Effect of Casopitant, a Novel NK‐1 Receptor Antagonist, on the Pharmacokinetics and Pharmacodynamics of Steady‐State Warfarin
The Journal of Clinical Pharmacology·2010
Mechanism and Management of AKT Inhibitor-Induced Hyperglycemia
Clinical Cancer Research·2008· 123 cited
Identification of 4-(2-(4-Amino-1,2,5-oxadiazol-3-yl)-1-ethyl-7-{[(3<i>S</i>)-3-piperidinylmethyl]oxy}-1<i>H</i>-imidazo[4,5-<i>c</i>]pyridin-4-yl)-2-methyl-3-butyn-2-ol (GSK690693), a Novel Inhibitor of AKT Kinase
Journal of Medicinal Chemistry·2008· 155 citedOpen Access
Effect of casopitant, a novel neurokinin -1 (NK-1) receptor antagonist for prevention of chemotherapy induced nausea and vomiting (CINV), on the pharmacokinetics (PK) and pharmacodynamics (PD) of steady-state warfarin
Journal of Clinical Oncology·2008· 4 cited
Role of glycogenolysis and reduced glucose uptake in AKT inhibitor-induced hyperglycemia
2008
Characterization of an Akt Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity
Cancer Research·2008· 296 citedOpen Access
Identification of a novel inhibitor of AKT kinase, GSK690693.
2007
Retraction
Science·2002· 8 cited
Prevention of Chemotherapy-Induced Alopecia in Rats by CDK Inhibitors
Science·2001· 167 cited
Dominant negative mutants of mitogen-activated protein kinase pathway
Methods in enzymology on CD-ROM/Methods in enzymology·2001· 11 cited
THE STRUCTURE OF CDK2/CYCLIN A IN COMPLEX WITH AN OXINDOLE INHIBITOR
2000
THE STRUCTURE OF CYCLIN-DEPENDENT KINASE 2 (CDK2) IN COMPLEX WITH AN OXINDOLE INHIBITOR
2000
page 1 of 2Next →

Frequent Co-authors

Victoria B. Knick(15), Jason A. Kahana(12), Nelson Rhodes(11), Dirk A. Heerding(11), Derek R. Duckett(11), Timothy J. Lansing(11), Anthony E. Choudhry(11), Zhihong Lai(11), Jack D. Leber(11), Elisabeth A. Minthorn(11), Edgar R. Wood(11), Randy T. McConnell(10), Tona M. Gilmer(10), Kimberly A. Robell(10), Robert S. Geske(10), Elena Kleymenova(10), Susan L. Strum(10), Pearl S. Huang(10), Robert A. Copeland(10), Shuyun Zhang(8)